Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China

Table 2

Efficacy endpoints (HbA1c, FPG, and 2hPG) at week 24.

Parameter	Liraglutide ()	Dapagliflozin ()
HbA1c (%)
Baseline
Week 24
Change from baseline^a	-2.14^c (-2.45~-1.85)	-1.78^c (-2.01~-1.55)
Change vs. dapagliflozin^b
FPG (mmol/l)
Baseline
Week 24
Change from baseline^a	-2.95^c (-3.52~-2.39)	-2.83^c (-3.40~-2.26)
Change vs. dapagliflozin^b
2hPG (mmol/l)
Baseline
Week 24
Change from baseline^a	-7.47^c (-9.14~-5.79)	-6.36^c (-7.87~-4.85)
Change vs. dapagliflozin^b

Abbreviations: FPG: fasting peripheral blood glucose; 2hPG: 2-hour postprandial peripheral blood glucose. ^a test of paired samples before and after treatment, . ^bIndependent sample test of change value between two groups. ^cMean change (95% confidence interval).